EUCTR2006-000974-54-IS进行中（未招募）不适用
A multi-centre, randomized, parallel groups, vehicle and active controlled study of amorolfine 4% and 10% nail lacquer new formulation in the topical treatment of distal and lateral subungual toenail onychomycosis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female adult aged 18 to 65.
- •2. Subject with clinically suspected distal and lateral subungual onychomycosis due to dermatophytes and involving at least one great toe nail to be selected as the Target Toenail” for planimetry.
- •3. At least one great toenail with at least 25% of the nail surface area with disease involvement but no involvement of the proximal 1/3 of the nail.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subject with clinically important abnormality which could interfere with the objectives of the study or the interpretation of the findings.
- •2. Subject with the presence of spikes or subungual dermatophytoma.
- •3. Subject with total dystrophic, white superficial or proximal onychomycosis
研究者
相似试验
进行中（未招募）
不适用
A multi-centre, randomized, parallel groups, vehicle and active controlled study of amorolfine 4% and 10% nail lacquer new formulation in the topical treatment of distal and lateral subungual toenail onychomycosisDistal and lateral subungual onychomycosisMedDRA version: 8.1Level: LLTClassification code 10030338EUCTR2006-000974-54-DEGALDERMA Research & Development132
进行中（未招募）
不适用
A multi-centre, randomized, parallel groups, vehicle and active controlled study of amorolfine 4% and 10% nail lacquer new formulation in the topical treatment of distal and lateral subungual toenail onychomycosisEUCTR2006-000974-54-CZGALDERMA Research & Development132
进行中（未招募）
1 期
Clinical study in early PD patients to investigate the effect of Opicapone 50mg or Levodopa 100 mg in the treatment of motor fluctuations.Parkinson's Disease (PD)MedDRA version: 20.0Level: HLTClassification code 10034005Term: Parkinson's disease and parkinsonismSystem Organ Class: 100000004852EUCTR2020-002754-24-ITBIAL-Portela & Ca, S.A.100
进行中（未招募）
1 期
Clinical study in early PD patients to investigate the effect of Opicapone 50mg or Levodopa 100 mg in the treatment of motor fluctuations.Parkinson's Disease (PD)MedDRA version: 20.0Level: HLTClassification code 10034005Term: Parkinson's disease and parkinsonismSystem Organ Class: 100000004852EUCTR2020-002754-24-ESBial - Portela & Ca, S.A.100
进行中（未招募）
1 期
Clinical study in early PD patients to investigate the effect of Opicapone 50mg or Levodopa 100 mg in the treatment of motor fluctuations.EUCTR2020-002754-24-PTBial - Portela & Ca, S.A.100